These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12132051)

  • 1. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation.
    Kusnierczyk NM; Saunders EF; Dupuis LL
    Bone Marrow Transplant; 2002 Jul; 30(2):119-24. PubMed ID: 12132051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
    Abbott B; Ippoliti C; Bruton J; Neumann J; Whaley R; Champlin R
    Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed nausea and vomiting in children receiving antineoplastics.
    Dupuis LL; Lau R; Greenberg ML
    Med Pediatr Oncol; 2001 Aug; 37(2):115-21. PubMed ID: 11496349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling conditioning-related emesis in children undergoing bone marrow transplantation.
    Mehta NH; Reed CM; Kuhlman C; Weinstein HJ; Parsons SK
    Oncol Nurs Forum; 1997 Oct; 24(9):1539-44. PubMed ID: 9348595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?
    Antonarakis ES; Evans JL; Heard GF; Noonan LM; Pizer BL; Hain RD
    Pediatr Blood Cancer; 2004 Nov; 43(6):651-8. PubMed ID: 15390297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypnosis in the prevention of chemotherapy-related nausea and vomiting in children: a prospective study.
    Jacknow DS; Tschann JM; Link MP; Boyce WT
    J Dev Behav Pediatr; 1994 Aug; 15(4):258-64. PubMed ID: 7798371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation.
    Abbott B; Ippoliti C; Hecth D; Bruton J; Whaley B; Champlin R
    Bone Marrow Transplant; 2000 Jun; 25(12):1279-83. PubMed ID: 10871733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.